1Wang JF,Zhang CC, Chou KC, et al. Structure of eytoehrome p450s and personalized drug[J].Curr Med Chem,2009,16(2):232-244.
2Avenoso A, Facciold G,Scordo MG,et al. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers[J]. Ther Drug Monit, 1999,21 (5) : 577-579.
3Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy[J]. J Clin Pharm Ther, 2000,25 (3) : 197-220.
4Forget P, le Polain de Waroux B, Wallemacq P, et al. Life-theratening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer:a single case re-exposure study[J]. J Pain Symptom Manage, 2008,36(1) : 92-96.
5Fleming J, Chetty M. Psychotropie drug interactions with valproate[J]. Clin Neuropharmacol, 2005,28(2) : 96-101.
6Kudo S, Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation [J ]. Eur J Clin Pharmaeol,1998,54(3):253-259.
7Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone [ J ]. Ann Pharmacother, 2002,36 (5) : 827-830.
8Niwa T,Shiraga T,Ishii I,et al. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs[J]. Biol Pharm Bull,2005,28(9):1711-1716.
9Spina E, Scordo MG, d'Arrigo C. Metabolic drug interaction with new psychotropic agent[J]. Fundam Clin Pharmacol, 2003,17(5):517-538.
10Antia U, Tingle MD, Russell BR. Metabolic interactions with piperazine-based 'party pill' drugs[J]. J Pharm Pharmaeol, 2009,61 (7), 877-882.
2Michelson D,Allen AJ,Busner J,et al.Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder:a randomized,placebo-controlled study[J].Am J Psychiatry,2002,159(11):1896-1901.
3Kelsey DK,Sumner CR,Casat CD,et al.Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder,including anassessment of evening and morning behavior:a double-blind,placebo-controlled trial[J].Pediatrics,2004,114(1):e1-8.
4Newcorn JH,Sutton VK,Weiss MD,etal.Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder:the Integrated Data Exploratory Analysis(IDEA)study[J].J Am Acad Child Adolesc Psychiatry,2009,48(5):511-518.
5American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders:DSM-IV-TR[M].Washington,DC:American Psychiatric Association,2000:78-85.
6龚耀先,蔡太生.中国修订韦氏智力儿童智力量表手册[M].长沙:湖南地图出版社,1993.
7Stein MA,Sarampote CS,Waldman ID,et al.A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder[J].Pediatrics,2003,112:e404.
8Steele M,Jensen PS,Quinn DM.Remission versus response as the goal of therapy in ADHD:a newstandard for the field?[J].Clin Ther,2006,28(11):1892-1908.
9Samer CF,Lorenzini KI,Rollason V,et al.Applications of CYP450testing in the clinical setting[J].Mol Diagn Ther,2013,17(3):165-184.
10Ramoz N,Boni C,Downing AM,et al.A haplotype of the norepinephrine transporter(Net)gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder(ADHD)[J].Neuropsychopharmacology,2009,34(9):2135-2142.
